In addition, with its higher efficacy in reducing GH and IGF-1 levels compared with fg-SRLs, PAS has shown a detrimental effect on glucose metabolism since early studies on healthy volunteers and clinical trials in patients with acromegaly [25]. The gene discussed is GH1; the disease is acromegaly.